Holm Eggemann

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai et al. · New England Journal of Medicine · 2012 · 528 citations

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

Atanas Ignatov, Tanja Ignatov, Christine Weißenborn et al. · Breast Cancer Research and Treatment · 2011 · 167 citations · Full text

Breast Oncology, G Protein-coupled Receptor, Medicine +7

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

Holm Eggemann, Atanas Ignatov, Bobbie J. Smith et al. · Breast Cancer Research and Treatment · 2012 · 160 citations

Breast Oncology, Oncology, Medicine +7

Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

B. Gerber, Sibylle Loibl, Holger Eidtmann et al. · Annals of Oncology · 2013 · 151 citations · Full text

Breast Oncology, Gbg 44, Geparquinto Study +10

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

W. Eiermann, Mahdi Rezai, Sherko Kümmel et al. · Annals of Oncology · 2012 · 145 citations · Full text